Search publications

Reset filters Search by keyword

No publications found.

 

Basic Science and Pathogenesis

Author(s): Borrie MJ; Phillips NA; Best S; Anastasiou-Ventura P; Aydogan T; Beaudoin C; Beuk J; Celotto I; Cole L; Das S; Fogarty J; Fouquet C; Gnassi L; Henri-Bellemare C; Pilon R; Sands J; Stirbu A; Truemner J; Chan S; Tucker A; Gajraj J; Bhangu ...

Background: The Comprehensive Assessment of Neurodegeneration and Dementia (COMPASS-ND) used wide inclusion criteria recruiting participants across the spectrum from normal cognition to cognitive impairment to all types of clinical dementia, including mixed dementia. 1173 participants comprising ...

Article GUID: 41435411


Public Health

Author(s): Gurve D; Centen AP; Slack PJ; Dang-Vu TT; Belleville S; Anderson ND; Montero-Odasso M; Nygaard HB; Chertkow H; Feldman HH; Brewster PWH; Lim A;

Background: Older adults experience considerable day-to-day variability in cognitive function. We aimed to test the hypothesis that this is in part related to sleep, and determine which EEG sleep features are most important in supporting day to day cognitive resilience. Method: We analyzed data ...

Article GUID: 41434309


Peripheral inflammation in a Canadian cohort of neurodegenerative conditions: Occurrence, determinants, and impact

Author(s): Seixas-Lima B; Rosa-Neto P; Phillips NA; Borrie M; Roncero CT; Lahiri D; Dori D; Eintracht S; Chertkow H;

Background"Inflammaging" describes chronic low-grade inflammation observed in aging individuals. It may play a major role in neurodegeneration.ObjectiveTo assess blood inflammatory markers in older adults. We hypothesized that elevated inflammation would be found in some cognitively nor ...

Article GUID: 41358624


Use of lecanemab and donanemab in the Canadian healthcare system: Evidence, challenges, and areas for future research

Author(s): Smith EE; Phillips NA; Feldman HH; Borrie M; Ganesh A; Henri-Bhargava A; Desmarais P; Frank A; Badhwar A; Barlow L; Bartha R; Best S; Bethell J; Bhangu J; Black SE; Bocti C; Bronskill SE; Burhan AM; Calon F; Camicioli R; Campbell B; Coll ...

Lecanemab and donanemab are monoclonal antibody therapies that remove amyloid-beta from the brain. They are the first therapies that alter a fundamental mechanism, amyloid-beta deposition, in Alzheimer disease (AD). To inform Canadian decisions on approval and use of these drugs, the Canadian Con ...

Article GUID: 39893139


Basic Science and Pathogenesis

Author(s): Lima BS; Rosa-Neto P; Phillips N; Borrie M; Roncero CT; Lahiri D; Dori D; Chertkow H;

Background: A growing body of research has focused on inflammation as both a potential biomarker and a risk factor for Alzheimer's disease (AD). The cytokine Interleukin-6 (IL-6) is involved in the pathogenesis of inflammatory disorders and in the physiological homeostasis of neural tissue. AD has been associated with increased IL-6 expression in brai ...

Article GUID: 39751468


Impact of a national dementia research consortium: The Canadian Consortium on Neurodegeneration in Aging (CCNA)

Author(s): Chertkow H; Phillips N; Rockwood K; Anderson N; Andrew MK; Bartha R; Beaudoin C; Bélanger N; Bellec P; Belleville S; Bergman H; Best S; Bethell J; Bherer L; Black S; Borrie M; Camicioli R; Carrier J; Cashman N; Chan S; Crowshoe L; Cuello ...

The Canadian Consortium on Neurodegeneration in Aging (CCNA) was created by the Canadian federal government through its health research funding agency, the Canadian Institutes for Health Research (CIHR), in 2014, as a response to the G7 initiative to fight dementia. Two five-year funding cycles ( ...

Article GUID: 39636028


A person with frontotemporal dementia shows increased metabolic rate across multiple brain regions after a series of tDCS sessions

Author(s): Roncero C; Nikelski J; Soucy JP; Lahiri D; Seixas-Lima B; Chertkow H;

No abstract available

Article GUID: 37182684


Consensus Statement Regarding the Application of Biogen to Health Canada for Approval of Aducanumab

Author(s): Chertkow H; Rockwood K; Hogan DB; Phillips N; Montero-Odasso M; Amanullah S; Black S; Bocti C; Borrie M; Feldman H; Freedman M; Hsiung R; Kirk A; Masellis M; Nygaard H; Rajji T; Verret L;

Alzheimer's disease is a major cause of morbidity and mortality. Currently, there are no disease-modifying pharmacotherapies for this condition. Aducanumab, an amyloid beta-directed monoclonal antibody that targets aggregated forms of amyloid-beta in the brains of people with Alzheimer's ...

Article GUID: 34912492


Recommendations of the 5th Canadian Consensus Conference on the diagnosis and treatment of dementia.

Author(s): Ismail Z, Black SE, Camicioli R, Chertkow H, Herrmann N, Laforce R, Montero-Odasso M, Rockwood K, Rosa-Neto P, Seitz D, Sivananthan S, Smith EE, Soucy JP, Vedel I, Gauthier S, CCCDTD5 participants

Alzheimers Dement. 2020 Jul 29;: Authors: Ismail Z, Black SE, Camicioli R, Chertkow H, Herrmann N, Laforce R, Montero-Odasso M, Rockwood K, Rosa-Neto P, Seitz D, Sivananthan S, Smith EE, Soucy JP, Vedel I, Gauthier S, CCCDTD5 participants

Article GUID: 32725777


Clinical judgement is paramount when performing cognitive screening during COVID-19.

Author(s): Phillips NA, Andrews M, Chertkow H, Pichora-Fuller MK, Rockwood K, Wittich W

J Am Geriatr Soc. 2020 May 12;: Authors: Phillips NA, Andrews M, Chertkow H, Pichora-Fuller MK, Rockwood K, Wittich W PMID: 32396983 [PubMed - as supplied by publisher]

Article GUID: 32396983


Special issues on using the MoCA for remote assessment during COVID-19 2.

Author(s): Phillips NA, Chertkow H, Pichora-Fuller MK, Wittich W

J Am Geriatr Soc. 2020 Apr 06;: Authors: Phillips NA, Chertkow H, Pichora-Fuller MK, Wittich W PMID: 32253754 [PubMed - as supplied by publisher]

Article GUID: 32253754


-   Page 1 / 2   >